Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

American Oriental Reveals Huge Acquisition in Q2 Report

publication date: Aug 12, 2008

American Oriental Bioengineering, Inc. announced in its Q2 earnings announcement that it signed a letter of intent to acquire an unnamed China pharmaceutical distribution company. In the follow-up earnings call with analysts, management said that it would pay $110 million to purchase a company with $550 million in annual revenues. In response to questions, American Oriental refused to disclose the profitability of the company. However, the company did say that margins for the potential acquisition are “above the industry standard,” which is usually below 5%. The company also announced much higher revenues and profits in its Q2 report. More details...

Stock Symbol: (NYSE: AOB)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital